

EuroGCT D4-1: Landscape mapping, report on mapping of European cell and gene therapy landscape at multiple levels

Aurélie Mahalatchimy, Hsin-Yu Kuo, Luc-Sylvain Gilbert, Auxane Delage,

Clare Blackburn

▶ To cite this version:

Aurélie Mahalatchimy, Hsin-Yu Kuo, Luc-Sylvain Gilbert, Auxane Delage, Clare Blackburn. EuroGCT D4-1: Landscape mapping, report on mapping of European cell and gene therapy landscape at multiple levels. European Commission - CORDIS. 2023, https://cordis.europa.eu/project/id/965241/results. halshs-04290642

HAL Id: halshs-04290642 https://shs.hal.science/halshs-04290642

Submitted on 16 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Deliverable Report

Grant Agreement Number: 965241

Project acronym: EuroGCT

Project title: European Consortium for Communicating Gene and Cell Therapy Information

Deliverable: D4.1. Landscape Mapping

Report on mapping of European cell and gene therapy landscape at multiple levels

Date: 31st July 2023

Deliverable 4.1



Project			
Project acronym:	EuroGCT		
Project full title:	European Consortium for Communicating Gene and Cell Therapy Information		
Grant agreement no.:	965241		
Funding scheme:	Co-ordination and Support Action		
Project start date:	1 February 2021		
Project duration:	60 months		
Call topic:	SC1-HCO-19-2020 - Reliable and accessible information on cell and gene-based therapies		
Project website:	www.eurogct.org		
Document			
Deliverable number:	D4.1		
Deliverable title:	Landscape mapping, report on mapping of European cell and gene therapy landscape at multiple levels		
Due date of deliverable:	Month 30		
Associated Milestones	NA		
Actual submission date:	31 July 2023		
Last Editor:	Aurélie MAHALATCHIMY		
Contributors:	Aurélie MAHALATCHIMY, Hsin-Yu KUO, Luc- Sylvain GILBERT, Auxane DELAGE, Clare Blackburn		
Work Package no.:	4		
Work Package title:	An Information and Engagement Hub for the Research and Regulatory Communities		
Work Package lead beneficiary:	2-AMU		
Work Package participants:	All partners		
Dissemination level:	Public		
Nature:	Report		
Draft/Final:	Final		
No of pages (including cover):	19 (Main report) + 12 (Annexe)		



Table of Contents

De	live	erab	le Re	eport	1
				pe mapping, report on mapping of European cell and gene therapy landscape at	5
1	I	ntro	ducti	on	5
2	5	Sum	mary	/	5
3	C	Dev	elopr	nent of an inventory of information and links on information and guidance	6
	3.1	De	velop	oment of EuroGCT original resources	6
	З	3.1.1	1	Ongoing content development for all entries within the 'Research Pathways' tree	6
	З	3.1.2	2	Network of Expertise (NoE) resources	6
	З	3.1.3	3	Multiple levels	7
	3.2		Co-o	developing resource through collaborations	7
	3.3		Sign	posting to existing resources	8
	З	3.3.1	1	EuroGCT Partner's resources	8
	З	3.3.2	2	External resources	8
	З	3.3.3	3	External resources through searches	8
	3.4		Res	earch Pathways Databaseupdated structure and information organisation	9
	3	3.4.´	1	Website structure	9
	З	3.4.2	2	Tagging with taxonomy terms	. 10
	З	3.4.3	3	New search and filter functions	. 12
	З	3.4.4	4	Direct access to topical sections	. 12
	З	3.4.5	5	Multiple entry points	. 12
	З	3.4.6	6	Visual elements and user experience	. 13
	3.5		Res	earch Pathways Coverage	. 13
4 en				practical guidelines and concise format fact sheets for researchers approaching or development of new therapies	. 15
	4.1		Con	nplexity in therapy classification	. 15
	4.2		New	/ content type—Case Study	. 17
5	C	Con	clusio	on and future steps	. 18
6	L	_ist	of An	inexes	. 19
				. Summary of activities and outputs: all published EuroGCT original resources in Pathways	. 19



List of acronyms

ATMP: Advanced Therapy Medicinal Products

EuroGCT: The European Consortium for Communicating Gene and Cell Therapy Information

IMHT: The EuroGCT Information Management Hub Team, comprised of project staff employed directly by the project, based at the University of Edinburgh (UEDIN) and Aix-Marseille University (AMU)

- ELSI: Ethical, Legal and Societal Issues
- **EMA:** European Medicines Agency
- EU: European Union
- **GA:** Grant Agreement
- ICH: The International Council for Harmonisation of Technical Requirements for
- Pharmaceuticals for Human Use
- NoE: Gene and Cell Therapy Network of Expertise
- WP: Work Package



D4.1 Landscape mapping, report on mapping of European cell and gene therapy landscape at multiple levels

1 Introduction

WP4, entitled "An Information and Engagement Hub for the Research and Regulatory Communities", is focussed on development of an information hub for the research and regulatory communities, that facilitates access of these communities to information on the practical steps needed for cell and gene-based therapy development and promotes information exchange within and between these communities. Once developed, this tailored section will create a 'one-stop shop' on where to seek further information and guidance relating to manufacturing guidelines, regulatory requirements, intellectual property rights, market acceptability and ethical matters related to advanced therapies development. WP4 will also promote liaison between cell and gene-based therapy stakeholders and the regulatory agencies.

As part of this development, a key objective of WP4 is to map the European cell and genebased therapies landscapes at multiple levels, *encompassing:*

(i) Practical steps required for advanced therapies development including: manufacturing guidelines (including analytics/characterisation), legal, regulatory (including preclinical testing strategies) and ethical and socio-economic aspects (including patient attitudes, health economics and market acceptability)

(ii) Activity related to cell and gene therapy development including: the academic, clinical and industrial (contract research organisations, biotech, pharma) landscapes, health economists and government agencies.

and to use this information to provide:

(iii) a set of practical guidelines and concise format fact sheets for researchers approaching or engaged with development of new therapies,

(iv) an inventory of information and links on where to seek further information and guidance

(v) a multi-layered searchable map of the cell and gene-based therapy landscape in Europe, mounted on www.eurogct.org and openly accessible.

Tasks (i) and (ii) above were reported in **D4.8**, submitted in the first reporting period. **D4.1** therefore reports on (iii) and (iv); (v) will be reported in month 48.

2 Summary

Deliverable 4.1 is a report on the mapping of the European gene-based and cell therapies landscape. This deliverable provides an update to the earlier deliverable, *D.4.8 Initial Landscape Mapping*, which was submitted in the first reporting period. **D4.8** reported the mapping, performed by EuroGCT, of the European landscapes associated with gene and cell therapy related product development pathways including ethical, legal, regulatory and societal issues (ELSI). Related, *D4.7 Information collation*, also submitted in the first reporting period, detailed our methodology for information collection and curation. The work reported in **D4.7** and **D4.8** resulted in creation of a development framework for a practical tool entitled "Development pathways for bringing gene and cell therapies from the lab to patients" with the

Deliverable 4.1



short website name of "Research Pathways" (see **D4.8**). This tool was organised as a Web tree, into which general information on the development pathways for bringing gene and cell therapies from the lab to patients (hereafter the "Research Pathways Tree") was organised. The Research Pathways Tree also included the organised information (mapping/inventory of information) of the practical steps required for cell and gene therapy development in Europe as well as links on relevant and existing information and guidance.

The present report, **D4.1**, therefore moves beyond the initial mapping to focus on implementation of these processes. This has required a combination of actions: Identification of the detailed information required to populate the Research Pathways Tree was described in **D4.8**; in this reporting period, we have: 1) created original EuroGCT resources around development pathways for bringing gene and cell therapies from the lab to patients, the Research Pathways Tree (see **D4.8 Annex 1** for details), 2) co-developed resources through collaboration, 3) selected and signposted to existing high quality resources (based on the methodology detailed in **D4.7**), and 4) launched an updated 'Research Pathways' database featuring improved navigability and information organisation. In the following sections, we provide the details of each action we have taken, our thought processes and some challenges we have come across.

The outputs are published on the EuroGCT website in the Research Pathways section (<u>www.eurogct.org/research-pathways</u>) as a searchable and filterable database and will continually be updated throughout the course of the project. (See also: **D4.2**).

3 Development of an inventory of information and links on information and guidance

This deliverable is built on the initial work reported in **D4.8** and further updated and populated with new information collated based on methodology listed in **D4.7**. In this section, we report the development and expansion processes of our information inventory, as well as the updates on website functions to facilitate user access.

3.1 Development of EuroGCT original resources

3.1.1 Ongoing content development for all entries within the 'Research Pathways' tree

The Research Pathways Tree is set out using a structure of entries and sub-entries (see **D4.8 Annexe 1**). In months 18-30, the writing of the full content of entries and sub-entries of the Research Pathways Tree has been implemented, agreed by the core ELSI team, using the sub-entry template shown in **D.4.8 Annexe 3**. The General Overviews drafts previously written for Research Pathways sub-entries (see **D.4.8 Annexes 4.a to 4.i**) have been further developed, completed and internally reviewed by the relevant ELSI groups.

3.1.2 Network of Expertise (NoE) resources

The scope of our 'Research Pathways' is vast, as it aims to cover information regarding gene and cell-based therapies broadly: mainly ATMPs, but also other gene and cell therapies that are not ATMPs such as 'Human body elements and medical devices', in accordance with our entry on 'Therapy Classification'. It also aims to cover information on product development,



especially on ATMPs, all the way from fundamental research to patient access (lab to patient), their technical and ELSI aspects.

To benefit from additional expertise and research interest on the ELSI aspects of gene and cell therapy, EuroGCT has involved the ELSI Network of Expertise (NoE) members drafting content. The entries drafted by NoE members have been internally reviewed and submitted for comments to the relevant ELSI Working Groups. Once finalised, these written entries will be published on the EuroGCT website.

Work is ongoing both to complete the Research Pathways section, and to inform researchers and regulators on the ongoing evolution of the European Union legislation in the field (e.g. proposal for a regulation on substances of human origin, proposal for a regulation and a directive reforming the pharmaceutical legislation).

3.1.3 Multiple levels

For this deliverable, we have adopted a multiple levels approach in the mapping of the gene and cell therapy landscape. For instance, in terms of legislative and regulatory aspects we focused on the EU law first, but we also link to national laws when it is possible and relevant. Indeed, national competent authorities, mainly in charge of implementing and overseeing the implementation of the EU legislation, can sometimes adopt more stringent measures on a national basis than those required by EU legislation, either in response to local epidemiological risks or considering that a higher level of safety can be ensured with more stringent provisions. This is the case in tissues and cells donor' testing requirements and blood donor' testing requirements.

In terms of legal classification, it is also necessary to encompass national and European levels of regulation to determine the applicable legal framework to gene and cell therapies. The consideration and the articulation of the different levels of regulations is illustrated in the "Human bodv elements for therapeutics applications" entrv (https://www.eurogct.org/research-pathways/therapy-classification/human-body-elementstherapeutic-applications) in the legal classification: for instance, the EU legislation on tissues and cells (directives) applies to the entire development chain of cells or tissues transplants, while it applies to the donation, collection/procurement and testing only regarding the development of advanced therapy medicinal products. Further steps of ATMPs' development depend on the EU pharmaceutical legislation (in particular, the ATMP regulation). As the directives need to be transposed into national laws while regulations have direct effect, the first steps of development of ATMPs are more dependent on national laws (national transpositions of directives and possible more stringent national rules) than further steps of their development that solely depend on European Union law (e.g., centralised marketing authorisation).

Finally, we are covering both binding EU legislation, and non-binding EU guidance and other resources. We are linking to these various levels of resources in terms of being binding or not.

3.2 Co-developing resource through collaborations

EuroGCT is part of a collaborative project named 'The Advanced Therapy Medicinal Products Patient and Public Involvement and Engagement Working Group (ATMP Engage)'. This collaboration brings together UK-based stakeholders with an interest in ATMPs to discuss and collaborate on Patient and Public Involvement and Engagement (PPIE) activity. The output of



this collaboration is the ATMP Engage PPI Directory (<u>https://www.eurogct.org/ppi-directory</u>). It contains patient and public involvement (PPI) resources for developers of cell and gene therapies, including toolkits, guidelines, advice, templates, and case studies. The resources collated within this directory spans EU and UK and are applicable to users independent of their geographical locations. The ATMP Engage PPI Directory constitutes the Patient and Public Involvement section of our Research Pathways database, and its content will be continuously updated and expanded during the project span.

3.3 Signposting to existing resources

3.3.1 EuroGCT Partner's resources

An important part of the work of WP4 is to signpost to additional existing resources on gene and cell therapy development relevant to the research and regulatory communities. To achieve this, we ask for consortium partners' input on resources produced by their organisations, or suggestions on information that were useful in their own research and development activities. Resources suggested by this route are then assessed, and promoted through links in the Research Pathways section as appropriate. A few examples of resources collected through this route include:

- Resources by ATMP Sweden (<u>https://www.eurogct.org/atmp-sweden-resources</u>)
- Resources by CGT Catapult (<u>https://www.eurogct.org/cell-and-gene-therapy-catapult-cgt-catapult-resources</u>)
- Resources by ATTC, managed by CGT Catapult (<u>https://www.eurogct.org/advanced-therapies-treatment-centre-attc-resources</u>)
- Resources by ECRIN (<u>https://www.eurogct.org/european-clinical-research-infrastructure-network-ecrin-resource</u>)

3.3.2 External resources

We similarly seek to link to resources produced externally to our partnership. Through our dissemination and networking activities reported in **D2.2**, we have connected with a number of organisations and projects external to EuroGCT. We have asked these organisations for their expert insight on helping us identify relevant resources produced by them or others. A non-exhaustive list of such resources include:

- European Advanced Translational Research Infrastructure in Medicine (EATRIS) resources (<u>https://www.eurogct.org/european-advanced-translational-research-infrastructure-medicine-eatris-resources</u>)
- European Joint Programme on Rare Diseases (EJP RD) resources (<u>https://www.eurogct.org/european-joint-programme-rare-diseases-ejp-rd-resources</u>)
- The Association of the British Pharmaceutical Industry (ABPI) Resources (<u>https://www.eurogct.org/association-british-pharmaceutical-industry-abpi-resources</u>)

3.3.3 External resources through searches

Additional resources are identified and collated by the Information Officer - product development pathway and the Information Officers - Ethics, Legal and Regulatory issues, according to the methodologies reported in **D4.7**.



3.4 Research Pathways Database--updated structure and information organisation

The EuroGCT online research and regulatory community hub, Research Pathways (**Figure 1**), is built on the initial information published (see deliverable **D4.9**). New information collated within the current reporting period is vast and mapping it onto the website requires careful planning on the content presentation, both structurally and functionally. Moreover, the nature of the information on product development is structurally complex—it requires cross-linking between sections and also represents interactions and/or parallel development effort between various stakeholders at every stage of development. Simultaneously, this organised information needs to make sense and remain findable by users. This presents a great challenge and a need in web development on features to support this complex information organisation and presentation. Below we report on each of these new features and functions and explains how they support the landscape mapping activity.




Figure 1. Screenshot of the Research Pathways search page (cropped).

3.4.1 Website structure

The IMHT undertook a review of the user experience for the Research Pathways section and have updated the section's original design from a hierarchical structure to a database model. This essentially translates to a flattened website structure for improved searchability and usability—resources that are originally buried at the bottom layer based on the hierarchical structure can now be exposed and becomes findable.



3.4.2 Tagging with taxonomy terms

The key to improved searchability is the thoughtfully designed taxonomies used for tagging. The taxonomies terms are used for pulling the tagged resource pages when a specific filter is applied. The IMHT has designed the set of taxonomy terms in **Table 1**:

Main filter category	Subcategory (1st layer)	Subcategory (2nd layer)
Theme	Research and Innovation	Fundamental Research Clinical research Translational Science Funding Incentives Early interaction with regulators
	Therapy classification	Legal classification ATMPs Not ATMPs: Human body elements for the therapeutic applications Not ATMPs: medical devices containing tissues and cells
	Manufacturing	Manufacturing Authorisation Good Manufacturing Practice Investigational medicinal products dossier Capability Scalability Packaging and labelling
	Commercialisation	Market access for ATMPs Distribution Advertising Pharmacovigilance Pricing & reimbursement
	Data	Data protection Data storage Data collection, processing, controlling Data sharing / Open Data Mission creep / data misuse
	Patient & Public Involvement	
Target audience	Ethics Researchers / developers Healthcare providers Public / patients Regulators Industry Other	
Region	EU/EEA EU (National level) UK North America Global Other	



Resource	Legal text	
Туре	Guides / Guidelines	
	Maps / Flowcharts	
	Forms / Checklists	
	Reports / Booklets	
	Presentation slides / Posters	
	Journal	
	Briefing / Blog posts	
	Case studies	
	Training / e-Learning / Webinar	
	Tools	
	Database / Repositories	
	Other	
Organisation	Regulatory Authorities	
type	Academic Bodies	
	Healthcare Providers	
	Industry	
	Patient Advocacy Organisations / Charity	
	Journal	
	Associations / Societies / Networks	
	Research Infrastructure / Research Centres	
	Translational Centres	
	Funding Bodies	
	Other	
Disease of	Blood	
focus	Immune Conditions	
	Eye	
	Muscle and Skeletal	
	Neurological	
	Other	

 Table 1. Taxonomy terms used in Research Pathways database

Theme filter is mainly based on the Research Pathways Tree structure reported in **D4.8**. Patient & Public Involvement and Ethics are added, as they are key topics running alongside the entire product development pathway. Resources specific to a type of therapy are tagged and can be searched for according to its legal classification (ATMPs, Not ATMPs: Human body elements for therapeutic applications, or Not ATMPs: medical devices containing tissues and cells).

Target audience filter refers to whom the resource is written for. Some resources are strictly targeting experts while some may be written in lay language.

Region filter concerns the geo- and political regions the information is effective in. For example, resources on regulations effective only within individual EU Member States will be tagged with the 'EU (National level)' tag, and not the 'EU/EEA tag'. Information on scientific development regardless of geo- or political region, or those indicated within the resource scope will be tagged with the 'Global' tag, examples include: ISSCR Guidelines for Stem Cell Research and Clinical Translation (<u>https://www.eurogct.org/isscr-guidelines-stem-cell-research-and-clinical-translation)</u>, WHO Human Genome Editing (HGE) Registry (<u>https://www.eurogct.org/who-human-genome-editing-hge-registry</u>) and more.

Resource type filter allows users to use the nature of the resource, whether it is a guideline, a database, a webinar, a journal article...etc to help narrow down search results.



Organisation type filter breaks down the type of organisations who produced the resources. For example, EuroGCT's original resources will be tagged as 'Associations / Societies / Networks'.

The **Disease of focus filters**, although not a primary focus for the Research Pathways section as the main attention is placed on the development process, can still be utilised in several ways. Users can use it to search for information related to the development of medicinal products related to specific types of condition if this information is available. It also provides a future handle to crosslink relevant information with the content that are hosted within the 'Discover' section of our site for the interested non-specialists to follow through.

3.4.3 New search and filter functions

To improve user experience in their searches, we introduced search functions including search by keywords, and checkboxes to apply filters to the taxonomy terms, and implemented the sorting by field and order.

3.4.4 Direct access to topical sections

Key Research Pathways section contains the collection of resources developed by EuroGCT WP4. The same set of resources can either be accessed directly through this hierarchicalstructured page, or by filtering/searching within the main database.

Key Pathway Resources section contains collated key resources on ATMP development by medicines agencies, and existing complementary work produced by other projects and organisations.

Case Studies section contains case studies on ATMP development. We will describe this new section in detail in the next section '4. A set of practical guidelines and concise format fact sheets for researchers approaching or engaged with development of new therapies.'

Patient and Public Involvement links to the ATMP Engage Patient and Public Involvement (PPI) Directory, a searchable and filterable directory with PPI resources for developers of cell and gene therapies.

Actors and Network section contains our initial mapping of stakeholders in ATMP development in Europe and beyond. This will be further developed and reported in **D4.3** which is due in month 48.

3.4.5 Multiple entry points

We have built in multiple entry points to access the same piece of information to facilitate user access, especially for key resources. This feature answers the expectations of various types of users, taking into account their different knowledge and experience, and consequently potential different approaches in looking for relevant information. For example, the ATMP Engage PPI database can be accessed through the links in the topical sections; it can also be accessed through the top menu as well as be searched for directly in the database. EuroGCT's original resources can be accessed through the 'Key Research Pathways' section as well as be searched for in the database. Key resources produced by other organisations can be found in the 'Key Pathway resources' topical section, and also be found directly in the database. We use multiple entry points to highlight the importance of these resources, and for drawing user's attention. It also considers the different knowledge and experience, and thus their possible different approaches in looking for relevant information.



3.4.6 Visual elements and user experience

We have implemented web design to improve visual presentations. We have also developed webpage features to enhance the crosslinking functions on the site, for example, the textboxes used in the Case Study content type (**Figure 2**) is clickable and links back to relevant search results in the main Research Pathways database.

The information regarding ATMP development is vast, complex and interconnected, and requires custom-designed website features and functions to support its presentation. We have developed features on our website to support this information mapping.

We anticipate the improved searchability and usability will greatly enhance users' experience in searching and navigating within the section, and in turn improve engagement and learning.

Clinical Research	
Research and Innovation	Table of contents
Long-term restoration of damaged corneal surfaces with autologous	Key Resources
cultivated corneal epithelium	Clinical Research
	Review Articles
Research and Innovation	Other Articles
Limbal Stem-Cell Therapy and Long-Term Corneal Regeneration	ATMP Classification
	EMA Authorisation Details
	HTA Evaluation
	Delivering Holoclar
Review Articles	Interview with Developers
	Further Reading
	Journal Article and Reviews
Research and Innovation Therapy classification Manufacturing Commercialisation	Eurostemcell Eye and Stem Cell Fa Sheet
Holoclar: first of its kind in more ways than one	News
This paper describes the regulatory pathway Holoclar took to achieve Marketing Authorisation.	
Manufacturing Commercialisation Navigating Market Authorization: The Path Holociar Took to Become the First Stem Cell Product Approved in the Surgeon Union	Back to Case Studies
An in-depth description on Notoclar manufacturing processes and quality requirements for marketing authorization	
Research and Innovation Manufacturing Commercialisation	
containing stem cells, in the EU	
An overview of the development process and recent developments, from early stage research to manufacturing. Oratains an executive summary of key considerations and challenges at various stages.	

Figure 2. Textboxes and features within case study content type enhances the linkage with relevant information in Research Pathways. This screenshot (cropped) is taken from: https://www.eurogct.org/case-study-holoclar.

3.5 Research Pathways Coverage

In this section, we report on the current coverage of the Research Pathways entries published on the Research Pathways database using 'Themes', as 'Theme' is built based on the draft tree reported in **D4.8**. **Table 2** below lists all Theme entries: marked in **green** are the entries that has the General Overviews published; marked in **blue** are those with full entries published; marked in **pink** are those only covered with signposting to external resources; marked in grey is covered by co-developed resources. See **Annexe 1** for a complete list and screenshots of published EuroGCT General Overviews and full entries.

Main filter	Subcategory (1st layer)	Subcategories (2nd layer and beyond)
category		



Theme	Research and Innovation	
meme	Research and innovation	Fundamental Research
		Clinical research
		Clinical trials
		Translational Science
		● <mark>Funding</mark>
		• Incentives
		 Intellectual Property rights
		 Patentability
		 Early interaction with regulators
		 Support for (innovative) medicines' development
		 Support for innovative medicines'
		development at the EMA level
		 Support for ATMPs' development
	Therapy classification	Legal classification
		• ATMPS
		ATMPs and Orphan medicinal products
		 Not ATMPs: Human body elements for the therapeutic
		applications
		 Not ATMPs: medical devices containing tissues and cells
	Manufacturing	Manufacturing Authorisation
	manaraotannig	
		Good Manufacturing Practice
		Investigational medicinal products dossier
		• <mark>Capability</mark>
		• <mark>Scalability</mark>
		Packaging and labelling
	Commercialisation	Market access for ATMPs
		 Standard Marketing authorization pathway: centralized
		procedure
		 Marketing Authorisation Application file
		 Expediting marketing authorisation pathways
		 Conditional MA
		 MA under exceptional circumstances
		 Accelerated Assessment Specificities of the marketing outboring time
		 Specificities of the marketing authorisation dossier for biosimilars
		Distribution
		Advertising
		Pharmacovigilance
		Pricing & reimbursement
	Data	• Data protection
		 Data Classification
		Main Principles
		Data Protection Authorities
		Data storage
		 Data collection, processing, controlling
		 Data sharing / Open Data
		Mission creep / data misuse
	Patient & Public Involvement	
	Ethics	

Table 2. Theme table to show current coverage of the published Research Pathways content.

Sub-entries within 'Market access for ATMPs' have all been completed and published on the Research Pathways information hub. Marketing authorisation constitutes the main mandatory step for ATMPs manufactured at the industrial scale to be commercialised in the European Union. These entries collectively provide summarised information in accessible language,



signpost to various relevant webpages on the EMA website, and links to external resources, notably EU binding legislation, guidance, and relevant literature. They provide users with easier access to the most relevant and high-quality information, and help them make sense of these various and complementary external resources. The sub-entries in 'Data' is also close to complete. These suites of information fulfil a 'one-stop-shop' for developers as required by the GA and will play a significant role in improving products development.

The curated information currently presents an almost full breadth of coverage for the Research Pathways. Besides the breadth of coverage, we are also working on increasing the depth of Research Pathways contents by publishing more resources written by the EuroGCT consortium. Several entries have been written in full and are under internal review or in the final drafting phase, including:

- Clinical trials;
- Patentability;
- Early interactions with regulators;
- Manufacturing Authorisation

As the project progresses, we will continue and reinforce our approach to collect information, write, review, and publish the content for each entry of the Research Pathways tree. The involvement of the Network of Expertise members will be continued and strengthened to achieve this objective.

We have started to see uptake by our online audience in several pieces of EuroGCT's original resources. The entries on 'Manufacturing Authorisation', and 'Packaging and labelling' are among the top-accessed pages within WP4. These pages appear in top 20 search results in Google using relevant query terms, and more often, are ranked within top 5 using exact search terms. We have also recorded a significantly longer user retention time for these EuroGCT original resource pages. More details on webpage traffic and online uptake can be found in **D2.2** and **D2.4**.

4 A set of practical guidelines and concise format fact sheets for researchers approaching or engaged with development of new therapies

4.1 Complexity in therapy classification

The practical guidelines for gene and cell therapies in development are dependent on their legal classification.

Therapy classification determines the legal mechanisms that govern the regulation of gene and cell therapies and subsequent guidelines to follow, but the classification is a non-trivial task for a therapy in development.

For Research Pathways, we focus on a subset of gene and cell therapies, ATMPs, although other gene and cell therapies that are not ATMPs but are transplants/transfusions or medical devices are also considered in the sub-entry on "therapy classification". The definitions of each type of ATMPs are listed according to EU law:

 For Gene Therapy Medicinal Product (GTMP) and Somatic Cell Therapy Medicinal Product (sCTMP): Directive 2001/83/EC, Annex I, Part IV, as modified by Commission Directive 2009/120/EC;



- Tissue Engineered Product (TEP): Article 2(1)(b) of Regulation (EC) No. 1394/2007
- Combined advanced therapy medicinal product (cATMP): Article 2(1)(d) of Regulation (EC) No. 1394/2007

Despite the legal definitions and criteria, it remains difficult to know exactly what kind of gene and cell therapy is being developed:

First, colloquial terms for therapies in development are often different from their legal classification. For example, authorised CAR-T cell therapies are considered gene therapy medicinal products (GTMPs) under current European Union legislations as opposed to its wordings 'cell therapies'. Another example is the therapy based on autologous chondrocytes for orthopaedic purposes (first ATMPs authorised in the EU, Chondrocelect, now withdrawn from the market by the marketing authorisation holder for commercial reasons) was generally called "cell therapy" although it was classified as a Tissue Engineered Product and not as a Cell Therapy Medicinal Product by the EMA/CAT.

Second, the classification for a therapy in development is also greatly dependent on the preparation steps. In the case of developing skin equivalents for healing skin wounds, different choices of the preparation steps results in different therapy classification:

- If cells are mechanically separated and sprayed on wound bed to help heal the wound:
 ⇒ this is not an ATMP.
- If growing epithelial cells (keratinocytes) from patient or donor's skin to stimulate healing:
 - \Rightarrow if enzymes are used to separate between epithelium and epidermis:
 - this therapy is an ATMP;
 - \Rightarrow if individual cells are isolated, and cultured in medium:
 - this therapy is a sCTMP;
 - \Rightarrow if combined with sheets, mesh, support scaffold:
 - this therapy is a cATMP.
- Alternatively, if the donor's dermis structure is used as a scaffold to graft on patient's wound bed, and then spray patient's keratinocyte cells on to this scaffold:
 - \Rightarrow this therapy is a TEP.

As therapy classification is a non-trivial task, EMA has advised that the final classification should be considered on case-by-case basis, and taking into account the scientific recommendation on ATMP classification provided by the EMA's Committee for Advanced Therapies (CAT).

Therefore, it is recommended for developers to contact regulators at the national and/or European levels (including mainly the EMA, national medicines agencies and national reimbursement bodies) as early as possible in order to clarify the regulatory pathway applicable the gene and cell therapy in development and their associated regulatory requirements and incentives.

In response to this need, we have built and presented key information in the Research Pathways entries. EuroGCT's original resources 'Therapy Classification' and its sub-entries within will help increase developers' understanding of therapy classification. Entries within 'Early interactions with regulators' will also help tackle the complexity of classification, as they encourage developers to get in touch with regulators early, and explain what services and procedures are established for supporting their development activities.



4.2 New content type—Case Study

In addition to presenting key information in Research Pathways, another step we took towards tackling the complexity of classification is to develop a new content type—Case Studies. It also aims to achieve Task 3 listed in GA (see page 5, task (iii) of this deliverable). The case studies pages collate existing resources including research articles, review articles, interviews, news articles, EMA authorisation details, HTA appraisals and more related to the development of specific products.

A dedicated case studies topical section (<u>https://www.eurogct.org/case-studies</u>, **Figure 3**) is set up to host the new content type, and can be accessed through the Research Pathways information hub. It currently contains two case studies for two approved ATMPs: 1) Holoclar, a Tissue Engineered Product (TEP), and 2) Strimvelis, a Gene Therapy Medicinal Product (GTMP). In these two case studies, we collated existing publicly available information about each stage of their development, from early-stage research to approval and beyond, to serve as a guide for the research community to learn about the development process, the keys to success, the challenges and how the developers overcame them.




Figure 3. Screenshot of the new Case Studies topical page (https://www.eurogct.org/case-studies).

As previously mentioned, the case study content type has specially designed features to implement the necessary complex crosslinking function to connect its various parts to the main Research Pathways database. Therefore, these case studies also serve a second purpose—they provide storylines for readers to walk through the resources collated in the Research Pathways database.

We are conscious that ATMPs have unique considerations and complexities at every stage in the development process, from pre-clinical and trial development to licencing and patient access. These considerations and complexities often are product specific. We will try to provide as many product development stories as possible, to help researchers find anchor points and use them as references to facilitate their own development activities.

There are more case studies for additional types of therapies in the pipeline. We are currently in the process of forming a collaboration with a team developing CAR-T therapy in Spain. Through this collaboration, we hope to co-develop a case study on their CAR-T therapy development to report on the key development processes, guidelines to follow, and serves as



a learning resource for the researcher and developer community. We are also in the process of co-developing a case study with the developers of Libmeldy, an EMA-approved GTMP.

Besides case studies that span the entire or a large part of the development pathway, we also hope to develop shorter case studies to capture researchers'/developers' practical considerations at specific time points during development. An example is about early classification considerations in developing skin equivalent for healing wounds--different choices of the preparation steps can result in different therapy classification (ATMP or not ATMP; if ATMP, which sub-type) and this in turn determines the requirements that the product must meet, and the relevant procedures leading to commercialisation. These short-format case studies are designed for experience-sharing among the researchers/developers' community. These small lightbulb moments and thoughts happening behind the scenes often are not revealed in research articles but will benefit many if shared with the community.

During the second half of the project, developing more case studies will be one of the main focuses. Contents will be published upon completion and iteratively updated throughout the project span.

5 Conclusion and future steps

EuroGCT has developed an indexed catalogue of resources and links through the following:

- 1) created a collection of EuroGCT's original resources for Research Pathways (Annexe 1);
- 2) collaborated and co-developed the ATMP-Engage Patient and Public Involvement (PPI) Directory;
- 3) selected and signposted to existing high quality resource;
- 4) launched an updated 'Research Pathways' database featuring improved navigability, information organisation and presentation. The custom-designed website features and functions supports the mapping of information developed and collated.

This catalogue of resources is mounted on the Research Pathways Information Hub and ensures the researcher and developer community can easily find the high-quality information they need throughout the product development process. It provides a 'one-stop-shop' for these communities and is anticipated to play a significant role in improving product development.

The new case studies topical section (<u>https://www.eurogct.org/case-studies</u>) contributes to tackling the complex issue of therapy classification that determines the legal mechanisms and subsequent guidelines a therapy in development has to follow. Considering each gene and cell therapy have unique considerations and complexities at every stage in the development process, we aim to increase the number and variety of therapy types in our case studies. We have rolled out two case studies on approved ATMPs, and are in the process of developing more content for this section. We are also developing shorter case studies for capturing practical considerations during a specific time point in development.

All of the above outputs are published on <u>EuroGCT's website</u> in the Research Pathways section (<u>www.eurogct.org/research-pathways</u>) as a searchable and filterable database with direct links to topical sections including the newly launched 'Case Studies' section. All contents within will continually be updated to increase the breadth and depth of our information mapping throughout the course of the project.



6 List of Annexes

Annexe 1. Summary of activities and outputs: all published EuroGCT original resources in Research Pathways





EuroGCT

Annex 1 to Deliverable D 4.1

Summary of activities and outputs

The General Overviews and the full entries contents of the 'research pathways' tree published within the Research Pathways section of the <u>EuroGCT website</u> are based on the following templates previously developed by the ELSI working group members:

EURO	Discover V Discover Gene and Cell Therapy	Research Pathways ~ Bringing new therapies from the lab to patients	About Us Our team and partners
Condition ~	Theme V		
Bringing therapies from	m the lab bench to patien sting to help guide throug	ts is a complex process. We'v h the development process -	e compiled
Find here information development.	and resources for researc	hers, regulators, and those in	terested in therapy
Learn more about F	Research Pathways		
https://www.eurogct.org	/research-pathways		










The General overviews and the full entries contents regarding "Research & Innovation" that have been published on the <u>EuroGCT website</u> are the following:







The General overviews and the full entries contents regarding "Therapy Classification" that have been published on the <u>EuroGCT website</u> are the following:


Condition v theme v theme v Search by keyword Q Hame / Research Pathways / Therapy Classification / ATMPs. / ATMPs and Orphan medicinal products Human body elect therapeutic apple therapy classification / ATMPs. ATMPS and Orphan medicinal products Research Pathways Introduction Introduction ATMPs Research Pathways Therapy Classification / ATMPs. ATMPs and Orphan medicinal products Introduction Introduction ATMPs ATMPs and Orphan medicinal products Introduction of the 7000 esisting and orphan medicinal products
Mast Advanced Therapy Medicinal Products (ATMs) that have been outhorised or marketing in the European Union, are obsciclastified as orphan medicinal products. Netwower on the equation is not an experimental contrary, during the revision process of European regulation on orphan medicinal products (advanced There(2000)). The obsci highlighted that the market of orphan medicinal products in divide the market of orphan medicinal products (advanced There(2000)). The obsci highlighted that the market of orphan medicinal products had "started to look more similar to "standard" medicines [[]] than innovative medicines [[]] than innovative https://www.eurogct.org/research-pathways/therapy-classification/atmps/atmps-and-orphan-medicinal_posterity of the control of the c





The General overviews and the full entries contents regarding "Manufacturing" that have been published on the <u>EuroGCT website</u> are the following:


EURO Discover Research Pathways About Us Discover Earre and Cel Binging new therapies therapy from the tab to potients Our team and pathwars	Contact Select language 🗸	EURO Discover Research Pathways About Us Discover Gave and Cell Bringing new therapies trom the lab to patients Our team and partners	Contactselect language v
Condition × Theme × Home / Research Pathways / Manufacturing / Manufacturing Authorisation	Search by keyword Q	Condition × Theme × Home / Research Pathways / Manufacturing / Good Manufacturing Practice	Search by keyword Q
Manufacturing Authorisation Introduction The manufacture of medicinal products in the European Union (EU) is subject to manufacturing authorisation. Any company wishing to manufacture a medicinal product mate hold a manufacturing authorisation issued by the national competent authority of the temper State where they carry out these activities. To obtain a manufacturing authorisation and medicinal products for human use intended for the European Union market must be produced in accordance with EU quality standards: Good Manufacturing Practice (GMP) principles and guidelines, and the European harmacopie), the requirements dopted for the manufacturing authorisation and the applicable legislation are respected.	Research Pathways Research and Innovation Therapy Classification Manufacturing Mathorisation Good Manufacturing Practice Packaging and labelling Commercialisation Actors and Networks Public Involvement and Data	Good Manufacturing Practice Introduction Under European Union (EU) law, the manufacture or import of medicinal products in the European Union is subject to manufacturing artimopat authorisation. Any company waking to manufacture a medicinal products must hald a manufacturing authorisation is subject to manufacture of medicination and the sub- national competent authority of the Member State where they carry out these activities. To a totain a menufacturing artimopart authorisation (and length and the sub- totain a menufacturing artimopart authorisation) and length and products for human use intended for the European Conomic Area. (AMP describes the minimum standard that of an declines manufacture must meet in their production and quality control processes, including these involving medicinal products that have been granted and marketing authorization as well as for the manufacture of	Research Pathways Research and Innovation Therapy Classification Manufacturing Manufacturing Authorisation Good Manufacturing Practice Packaging and Iabelling Commercialisation Actors and Networks Public Involvement and Data
https://www.eurogct.org/research- pathways/manufacturing/manufacturing	-authorisation	https://www.eurogct.org/research- pathways/manufacturing/good-manufac practice	turing-









The General overviews and the full entries contents regarding "Commercialisation" that have been published on the <u>EuroGCT website</u> are the following:


















The General overviews and the full entries contents regarding "Patient Involvement & Data" that have been published on the <u>EuroGCT website</u> are the following:















Actors and Networks

The 'Actors and Networks' contribution to the mapping of the European landscape related to gene and cell therapy is currently ongoing. This mapping encompasses multiple levels of actors and networks: international, national and regional ones. Some actors and networks have already been identified in the 'research pathways' entries and sub-entries in the 'Stakeholders' and 'Definition' sections and published on the <u>EuroGCT website</u>. The regulatory actors and networks landscape mapping will be regularly completed and updated and published alongside the completion of the entries and sub-entries contents.

The 'Actors and Networks' contents published on the EuroGCT website are the following:

euro	Discover Discover Gene and Cell Therapy	Research Pathways Bringing new therapies from the lab to patients	About Us Our team and partners	Contact	Select language N	/
Condition ~	Theme V			Search by	/ keyword	Q

Home / Research Pathways / Actors and Networks

Actors and Networks

The thriving field of gene and cell therapy is supported by a large community of academic, clinical, translational, industrial and patient organisations. This section maps the stakeholders and their activities in Europe and beyond.

Actors Activity Map

The EuroGCT project will develop a searchable map of the Advanced Therapy Medicinal Products (ATMP) landscape in Europe, including activity by stakeholders including academic, clinical, translational, industrial (contract research organisations, manufacturing facilities, biotech, pharma) and patient organisations.

In the meantime, please see:



Research Pathways

Research and Innovation Therapy Classification Manufacturing Commercialisation Actors and Networks Public Involvement and Data

Table of contents

Actors Activity Map Networks National Medicines Agencies National Health Technology Assessment (HTA) Bodies Research Ethics Committees Training Providers





Number Notices Page of the first sectors and account in spirate order orde	Naturalia	
 Particle for the function of set of the programments of the programment of the p	· · · · · · · · · · · · · · · · · · ·	<u>ATMP Sweden</u>
National international Societies - Ensure family display to be the constraint of the second society of of the second societ	networks, and societies representing gene and cell therapy researchers across Europe.	 ATMP Manufacturing Ireland Advanced Therapy Network (ATN) BioPhorum Cell and Gene Therapy (CGT) Deutsche Gesellschaft für Gentherapie e.V. (DG-GT) European Federation of Pharmaceutical Industries and Associations (EFPIA) European Patients' Forum (EPF) European Joint Programme on Rare Diseases (EJP RD) European Society for Blood and Marrow Transplantation (EBMT)
pathways/actors-and-networks pathways/actors-and-networks EUProjects •:uman Puriodent Stem Cell Registry (https://www.europathways/actors-and-networks COST Action CarGusters - The European Network for Stem Cell Core Facilities •:autorial Action Cercusters - The European Network for Stem Cell Core Facilities COST Action CarGusters - The European Network for Stem Cell Core Facilities •:autorial CarGusters - The European Network for Stem Cell Core Facilities Cost Action CarGusters - The European Network for Stem Cell Core Facilities •:action CarGusters - The European Network for Stem Cell Core Facilities Steward Facility of Medicines - Control Agency (or Medicines and Health Products (FAMRE)) •:adeparts (or medicinal products and medical Bevices and European Network for Stem Cell Core Facilities Steward Facility of Medicines - Thermosen Network for Stem Cell Core Facilities •:adeparts (or medicinal Eagency (or Medicines agency (or Medicines a	 International Society for Cell & Gene Therapy (ISCT) The International Society for Stem Cell Research (ISSCR) European Society of Gene & Cell Therapy (ESGCT) European Society of Human Genetics (ESHG) American Society of Gene & Cell Therapy (ASGCT) American Society of Gene & Cell Therapy (ASGCT) American Society of Gene and Gene Therapy (ASGCT) British Society for Gene and Cell Therapy (BSGCT) French Society of Cellular and Gene Therapy (ISFTCG) German Gene Therapy Society (DGGT) Netherlands Society of Gene and Cell Therapy (NVGCT) Swedish Society of Gene and Cell Therapy (SSGCT) 	 Forum for Innovative Regenerative Medicine (FIRM) The Global Alliance for iPSC Therapies (GAIT) Genetic Alliance UK HESI Cell Therapy—TRAcking, Circulation, and Safety (CT-TRACS) committee International Consortium for Personalised Medicine (ICPerMed) International Rare Diseases Research Consortium (IRDIRC) Stem Cells Australia The Advanced Therapy Treatment Centres (ATTC) Network The Association of the British Pharmaceutical Industry (ABPI) The International Alliance for Biological Standardization (IABS)
EU Projects Austria Austria Austria Austria Austria Austria Magency for Health and Eod Safety Begion Tederal Agency. for Medicines and Health Products (FAMHP) Begion Tederal Agency. for Medicines and Health Products (FAMHP) Begion Tederal Agency. for Medicines and Health Products (FAMHP) Begion Tederal Agency. for Medicines and Health Products (FAMHP) Begion Tederal Agency. for Medicines and Health Products (FAMHP) Begion Tederal Agency. For Medicines and Health Products (FAMHP) Begion Tederal Agency. For Medicines and Health Products (FAMHP) Begion Tederal Agency. For Medicines and Health Products (FAMHP) Begion Tederal Agency. Medicines Agency. Croatia Agency. Medicines Strangthming Training of Academia in Begulatory Science (CSA STARS) Tableata - a consortium working to accelerate the process of developing CAT r-cell therapy in the European Union (EU) A list of EU-Funded actions on substances of humon origin can be found here? Hittings Training of Academia in Begulatory Science (CSA STARS) Bethways/actors-and-networks https://www.eurogct.org/research-pathways/actors-and-networks Hittings Training Adminishing Agency (Medicines Carl (Medicines Agency (Medicines Agency (Medicines Agency (Me		
	 Human Pluripotent Stem Cell Registry (hPSCreg) COST Action HAPLO-IPS AUTOSTEM AIDPATH RESTORE EJP RD - European Joint Programme on Rare Diseases COST Action CorEuStem - The European Network for Stem Cell Core Facilities GAPP JOINT ACTION - Co-Funded by the Health Programme of the EU I-BioLex - Fragmentation and defragmentation of the law on biomedical innovations SIENNA Project Strengthening Training of Academia in Regulatory Science (CSA STARS) T2Evolve - a consortium working to accelerate the process of developing CAR T-cell therapy in the European Union (EU) A list of EU-Funded actions on substances of human origin can be found here 	 Austria Austrian Agency for Health and Food Safety Belgium Federal Agency for Medicines and Health Products (FAMHP) Bulgaria Bulgarian Drug Agency Croatia Agency for medicinal products and medical devices of Croatia Cyprus Ministry of Health - Pharmaceutical Services Czechia State Institute for Drug Control Demmark Danish Medicines Agency Estonia State Agency of Medicines Finland Einnish Medicines Agency France National Agency for the Safety of Medicine and Health Products Germany Ederal Institute for Drugs and Medical Devices Germany Ederal Institute for Drugs and Medical Devices Germany Ederal Institute of Pharmacy and Nutrition Iceland Icelandic Medicines Agency (AIFA) Italy Italian Medicines Agency (AIFA) Italy Italian Medicines Control Agency Ireland Health Products Regulatory Authority (HPRA) Italy Italian Medicines Control Agency Lischtenstein Office of Health / Department of Pharmaceuticals Lithuania State Medicines Control Agency Luxembourg Ministry of Health Matta Medicines Agency (INMA) Netherlands Medicines Agency (NMA) Netherlands Medicines Agency (NMA) Netherlands Medicines Agency (NMA) Poland Office for Registration of Medicinal products, Medical Devices and Biocidal Products Poland Office for Registration of Medicines and Health Products (INFARMED) Romanio National Authority of Medicines and Health Products (INFARMED) Romania Autional Authority of Medicines and Health Products (INFARMED) Stovenia Agency of Medicines and Health Products Stovenia Agency of Medicines and Health Products Stovenia Agency for Medicinea Products and Medical Devices of the Republic of Slovenia Sponi





